Pioglitazone might prevent the progression of slowly progressive type 1 diabetes

Intern Med. 2009;48(12):1037-9. doi: 10.2169/internalmedicine.48.1990. Epub 2009 Jun 15.

Abstract

Although recent studies recommended that insulin should be administered to patients with slowly progressive type 1 diabetes, even those with non-insulin dependent status, patients prefer oral hypoglycemic agents to insulin injections. We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (SigmaC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). This case suggests that pioglitazone might prevent or delay the loss of insulin secretion and insulin dependency in slowly progressive type 1 diabetic patients.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Disease Progression
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / blood
  • Insulin / therapeutic use
  • Male
  • Middle Aged
  • Pioglitazone
  • Thiazolidinediones / administration & dosage
  • Thiazolidinediones / therapeutic use*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Thiazolidinediones
  • Pioglitazone